Advertisement

Pediatric off-label use of psychotropic drugs approved for adult use in Japan in the light of approval information regarding pediatric patients in the United States: a study of a pharmacy prescription database

  • Nanae Tanemura
  • Maika Asawa
  • Mayuko Kuroda
  • Tsuyoshi Sasaki
  • Yoshiaki Iwane
  • Hisashi Urushihara
Original Article
  • 3 Downloads

Abstract

Background

Off-label use of psychotropic prescriptions for pediatric patients has been increasing in Japan. This study sought to clarify pediatric patients’ off-label use of psychotropics approved only for adults in Japan.

Methods

This retrospective study on psychotropic utilization employed a pharmaceutical health insurance claims database supplied by a pharmacy for the fiscal year 2016. Seven psychotropic drugs were examined. For each drug, we calculated the proportion of patients aged < 16 years or who were under the approved age limit set in the United States out of all patients. The maximum daily dose of each drug within the study period was plotted by age.

Results

Data of 45,715 patients (female: 26,799, male: 18,916) with 331,920 prescriptions were examined in this study. For each drug, the proportion of pediatric patients aged < 16 years ranged from 0.15 to 1.1%, while the proportion of those under the approved age limit in the United States ranged from 0 to 0.27%. Olanzapine had the highest reported proportion. No drugs other than olanzapine were taken under the approved age limit in the United States.

Conclusions

We identified the pediatric off-label use of psychotropics that were limited to adult use in Japan. The results indicated the possibility of referring to international guidelines or evidence in clinical practice, but these factors do not discount the existing problems with off-label use. More clinical trials within the pediatric population in Japan are needed to address the issue of off-label use and obtain useful and reliable information in the package inserts for rational use in future pediatric patients.

Keywords

Japan Off-label use Pediatric Prescription Psychotropic drug 

Notes

Acknowledgements

We would like to thank Editage (www.editage.jp) for English language editing.

Author contributions

All authors contributed to the design and implementation of this research, the analysis of the results, and writing of the manuscript. All authors approved the final version of the manuscript to be published.

Funding

None.

Compliance with ethical standards

Ethical approval

The study protocol was approved by the Keio University Faculty of Pharmacy Ethics Committee for research involving humans (No. 170707-1).

Conflict of interest

TS has received speakers’ honoraria from Daiichi Sankyo, Eli Lilly, Glaxo Smith Kline, Novartis, Janssen, Otsuka, Shionogi, Shire, Taisho and Tanabe Mitsubishi, and he has also received research support from Novartis, Otsuka, Shionogi and Taisho (from April 2014 to April 2018). YI is an employee of KRAFT Inc. HU is a consultant of Eisai Co., Ltd. No financial or non-financial benefits have been or will be received by NT, MA and KM from any party related directly or indirectly to the subject of this article.

Supplementary material

12519_2018_213_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 17 kb)

References

  1. 1.
    Shirkey HC. Therapeutic orphans-everybody’s business. Ann Pharmacother. 2006;40:1174.CrossRefGoogle Scholar
  2. 2.
    Sekimizu M. PMDA’s challenges in pediatric drug development. Regul Sci Med Prod. 2015;5:159–66 (in Japanese).Google Scholar
  3. 3.
    Nakagawa M. An unapproved and off-label use in circulatory area for pediatrics. Clin Psychiatry. 2016;79:863–9 (in Japanese).Google Scholar
  4. 4.
    Gore R, Chugh PK, Tripathi CD, Lhamo Y, Gautam S. Pediatric off-label and unlicensed drug use and its implications. Curr Clin Pharmacol. 2017;12:18–25.CrossRefGoogle Scholar
  5. 5.
    Frattarelli DA, Galinkin JL, Green TP, Johnson TD, Neville KA, Paul IM, et al. Off-label use of drugs in children. Pediatrics. 2014;133:563–7.CrossRefGoogle Scholar
  6. 6.
    Snyder KM, Reaman G, Avant D, Pazdur R. The impact of the written request process on drug development in childhood cancer. Pediatr Blood Cancer. 2013;60:531–7.CrossRefGoogle Scholar
  7. 7.
    Nakamura T. Current status on pediatric drug development tagetted for neuropsychiatric disorder. Jpn J Child Adolescent Psychiatry. 2017;58:76–84 (in Japanese).Google Scholar
  8. 8.
    Berdkan S, Rabbaa L, Hajj A, Eid B, Jabbour H, Osta NE, et al. Comparative assessment of off-label and unlicensed drug prescriptions in children: FDA versus ANSM guidelines. Clin Ther. 2016;38:1833–44.CrossRefGoogle Scholar
  9. 9.
    Kuroki S, Seguchi Y, Miyashita S, Uramura K, Yamashita H, Kodaira M. Treatment guidelines for depression at puberty in British and North America. Jpn J Clin Psychiatry. 2011;40:1203–12 (in Japanese).Google Scholar
  10. 10.
    Sachs AN, Avant D, Lee CS, Rodriguez W, Murphy MD. Pediatric information in drug product labeling. JAMA. 2012;307:1914–5.CrossRefGoogle Scholar
  11. 11.
    Hudgins JD, Bacho MA, Olsen KL, Bourgeois FT. Pediatric drug information available at the time of new drug approvals: a cross-sectional analysis. Pharmacoepidemiol Drug Saf. 2018;27:161–7.CrossRefGoogle Scholar
  12. 12.
    Imoto M. Challenges to Unapproved Drugs. Egul Sci Med Prod. 2015;5:121–34 (in Japanese).Google Scholar
  13. 13.
    Usami M, Iwadare Y, Kodaira M, Watanabe K, Saito K. Near infrared spectroscopy study of the frontopolar hemodynamic response and depressive mood in children with major depressive disorder: a pilot study. PLoS One. 2014;9:e86290.CrossRefGoogle Scholar
  14. 14.
    Ozaki M. Industries’ efforts in promoting pediatric drug development. Egul Sci Med Prod. 2015;5:151–8 (in Japanese).Google Scholar
  15. 15.
    Sohn M, Moga DC, Blumenschein K, Talbert J. National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (Baltimore). 2016;95:e3784.CrossRefGoogle Scholar
  16. 16.
    Kearns MA, Hawley KM. Predictors of polypharmacy and off-label prescribing of psychotropic medications: a national survey of child and adolescent psychiatrists. J Psychiatr Pract. 2014;20:438–47.CrossRefGoogle Scholar
  17. 17.
    Czaja AS, Valuck R. Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence. Pharmacoepidemiol Drug Saf. 2012;21:997–1004.CrossRefGoogle Scholar
  18. 18.
    Winterfeld U, Le Heuzey MF, Acquaviva E, Mouren MC, Brion F, Bourdon O. Off-label use of psychotropic medications in pediatric wards: a prospective study. Arch Pediatr. 2009;16:1252–60 (in French).CrossRefGoogle Scholar
  19. 19.
    Ministry of Health, Labour and Welfare. 2014. http://www.mhlw.go.jp/toukei/saikin/hw/kanja/14/index.html. Accessed 31 Mar 2018.
  20. 20.
    Nakagome K. Actual condition survey on psychotropic prescription. Tokyo: Health Labour Sciences Research Grant; 2013.Google Scholar
  21. 21.
    Okumura Y, Fujita J, Matsumoto T. Trends of psychotropic medication use among children and adolescents in Japan data from the national insurance claims database between 2002 and 2010. Seishin Shinkeigaku Zasshi. 2014;116:921–35 (in Japanese).PubMedGoogle Scholar
  22. 22.
    Ministry of Health, Labour and Welfare. 2017. https://www.mhlw.go.jp/file/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka/0000153339.pdf. Accessed 1 Apr 2017.
  23. 23.
  24. 24.
    Park RJ, Goodyer IM. Clinical guidelines for depressive disorders in childhood and adolescence. Eur Child Adolesc Psychiatry. 2000;9:147–61.CrossRefGoogle Scholar
  25. 25.
  26. 26.
    Hughes CW, Emslie GJ, Crismon ML, Posner K, Birmaher B, Ryan N, et al. Texas children’s medication algorithm project: update from texas consensus conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:667–86.CrossRefGoogle Scholar
  27. 27.
    Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.CrossRefGoogle Scholar
  28. 28.
    Yamada K. Guideline on treatment for bipolar disorder. Jpn J Clin Psychopharmacol. 2017;20:541–7 (in Japanese).Google Scholar
  29. 29.
    Miyata H, Ishii J. Psychopharmacology of antipsychotic drugs. J Pract Pharm. 2016;67:3186–92 (in Japanese).Google Scholar
  30. 30.
    Akiyama K. Pharmacological profile of antipsychotic drug. Clin Psychiatry. 2002;44:238–43 (in Japanese).Google Scholar
  31. 31.
    Usami M. Drug therapy with antidepressant in clinical psychiatry for child and adolescence. Jpn J Child Adolesc Psychiatry. 2017;58:146–56 (in Japanese).Google Scholar
  32. 32.
    Saito T. Current status on clinical trials tagetted for pediatrics with psychotropic. Jpn J Clin Psychopharmacol. 2013;16:1731–9 (in Japanese).Google Scholar
  33. 33.
    Hayashi H, Fujimaki C, Inoue K, Suzuki T, Itoh K. Genetic polymorphism of C452T (T127I) in Human γ-Glutamyl hydrolase in a Japanese population. Biol Pharm Bull. 2007;30:839–41.CrossRefGoogle Scholar

Copyright information

© Children's Hospital, Zhejiang University School of Medicine 2018

Authors and Affiliations

  1. 1.Division of Drug Development and Regulatory Science, Faculty of PharmacyKeio UniversityTokyoJapan
  2. 2.Department of Child PsychiatryChiba University HospitalChibaJapan
  3. 3.KRAFT Inc.TokyoJapan

Personalised recommendations